The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Forecasted Market Value Of The Seasonal Influenza Market Across 2026–2030?
The seasonal influenza market size has experienced rapid expansion in recent years. It is anticipated to increase from $9.85 billion in 2025 to $11.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.1%. Historically, this growth can be ascribed to elements such as seasonal flu outbreaks, restricted vaccine coverage, conventional diagnostic approaches, low public awareness, and challenges in regional distribution.
The seasonal influenza market is projected to experience substantial expansion in the coming years. By 2030, this market is forecasted to reach $21.39 billion, exhibiting a compound annual growth rate (CAGR) of 16.7%. Key factors driving this growth during the forecast timeframe include advancements such as universal vaccine development, swift point-of-care diagnostic tools, digital systems for immunization tracking, collaborative public-private vaccination initiatives, and improved supply chain efficiency. Significant trends expected throughout this period encompass universal flu vaccines, quick diagnostic tests, at-home vaccination services, expanding governmental immunization efforts, and the modernization of pharmaceutical supply chains.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21285&type=smp
What Drivers Are Shaping The Future Growth Of The Seasonal Influenza Market?
The anticipated expansion of the seasonal influenza market is linked to the rising incidence of respiratory infections. These infections are defined as conditions resulting from viral or bacterial agents impacting parts of the respiratory system, such as the sinuses, throat, airways, or lungs. Factors contributing to the increase in respiratory infection prevalence include air pollution, climate shifts, compromised immune systems, and the effortless spread of viruses in congested or inadequately ventilated environments. Seasonal influenza treatment offers multiple mechanisms to prevent or lessen the severity of respiratory infections, primarily by targeting the influenza virus and managing associated symptoms that might otherwise cause secondary complications. As an illustration, in October 2024, data from the UK Health Security Agency, a UK-based government agency, revealed a 10.7% year-over-year increase in tuberculosis (TB) cases (a respiratory infection caused by the bacterium Mycobacterium tuberculosis) in England during 2023, with the number of cases climbing from 4,380 in 2022 to 4,850. Consequently, the growing incidence of respiratory infections is expected to spur expansion in the seasonal influenza market.
What Segmentation Levels Are Considered In The Seasonal Influenza Market?
The seasonal influenza market covered in this report is segmented –
1) By Type: Influenza A Virus, Influenza B Virus, Influenza C Virus, Influenza D Virus
2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations
3) By Distribution Channel: Hospital, Government And institutional supply, Pharmacy, Online
4) By Treatment: Antiviral, Neuraminidase Inhibitors, Vaccination, Other Treatments
Subsegments:
1) By Influenza A Virus: Subtype H1N1, Subtype H3N2, Other Subtypes
2) By Influenza B Virus: Lineage Victoria, Lineage Yamagata
3) By Influenza C Virus: Seasonal C Virus, Non-seasonal C Virus
4) By Influenza D Virus: Animal-associated Influenza D, Zoonotic Surveillance And Research Applications
How Are Trends Impacting The Seasonal Influenza Market?
Major companies operating in the seasonal influenza market are concentrating on innovations in treatment, such as combination vaccines, to bolster immunity by targeting various strains of the virus, thereby enhancing effectiveness and reducing the necessity for frequent vaccinations. Combination vaccines provide protection against multiple diseases or strains with a single injection, minimizing the total number of shots required for immunization. For instance, in October 2023, Moderna, Inc., a US-based biotechnology company, announced positive interim Phase 1/2 trial results for mRNA-1083, its investigative combination vaccine aimed at both influenza and COVID-19. Crafted to improve compliance, streamline administration, and offer greater convenience for individuals and healthcare systems, mRNA-1083 is currently being evaluated for its safety and immunogenicity against standard flu vaccines Fluarix (ages 50-64) and Fluzone HD (ages 65-79), in addition to being compared with the Spikevax booster.
Which Leading Firms Are Contributing To The Growth Of The Seasonal Influenza Market?
Major companies operating in the seasonal influenza market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Merck KGaA, Moderna Inc., Boehringer Ingelheim International GmbH, Sinovac Biotech Ltd., Daiichi Sankyo Company Limited, CSL Limited, Genentech Inc., Shionogi & Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Bharat Biotech International Limited, Vaxart Inc., Inovio Pharmaceuticals Inc., SK bioscience Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., Altimmune Inc.
Read the full seasonal influenza market report here:
https://www.thebusinessresearchcompany.com/report/seasonal-influenza-global-market-report
Which Geographic Regions Are Influencing Demand In The Seasonal Influenza Market?
North America was the largest region in the seasonal influenza market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seasonal influenza market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Seasonal Influenza Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21285&type=smp
Browse Through More Reports Similar to the Global Seasonal Influenza Market 2026, By The Business Research Company
Influenza Vaccines Global Market Report
https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report
Influenza Treatment Global Market Report
https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report
Swine Flu Vaccination Global Market Report
https://www.thebusinessresearchcompany.com/report/swine-flu-vaccination-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model